By: Tamarack Advisors
For a link to the original article by Tamarack Advisors, go here.
BioLargo, Inc. (OTC: BLGO), a sustainable science and
technology company that has been inventing and validating breakthrough
technologies in water treatment, odor control, and advanced wound care for the
past 10 years, will be presenting at the 3rd annual technical symposium at the
University of Alberta in Edmonton AB.
The company will be speaking about their technology on
August 14, 2017, where they will showcase the results of the past year’s
commercial validation trials done with what they bill as their “low cost, high
impact” water treatment system, the AOS (Advanced Oxidation System). The
symposium, which is slated to also feature the commercial designs of the
technology, is by invitation only and not open to the public as it is geared
towards professionals in both the academic and business spaces.
Dennis Calvert, BioLargo’s CEO, previewed their presentation
for the symposium in a recent radio interview by Uptick Newswire. He also
discussed the company’s progress in commercializing its industrial odor control
products, and provided a brief update on its advanced wound care products that
are in the final stages of preparation for 510K applications with the FDA.
Here are the highlights of the Uptick interview and our follow
up conversation with Mr. Calvert:
• Signed
three National Purchasing Agreements (NPAs) in the past few months with
industry leading companies, that allow it to sell to over 1,000 solid waste
handling facilities and landfills. Note that the company has cautioned in their
SEC filings that these agreements merely provide “vendor status” authorizing
them to sell product to operating facilities with no obligation on the
customer’s part to purchase a minimum amount or even any product.
• The
company is targeting facilities based on size, location, and product usage
(projected monthly product usage ranges from $2,000 - $20,000 are ideal);
Calvert noted that the need for odor reduction products decreases at facilities
in cold climates during winter months and increases in more highly populated
areas.
• “Sales
are increasing.” Although Calvert didn’t elaborate during the interview, it’s
quarterly report is due mid-August.
• Waste
industry executives are relieved to find an odor control product that actually
works.
• Although
there are over 1,000,000 potential customer locations in the US, the company is
focused more narrowly on the solid waste and wastewater handling segments.
• There are
approximately 15,000 landfills alone in the United States.
Update on Clyra, Advanced Wound Care:
• Clyra
recently completed development of two advanced wound care products;
• The
rigorous testing required by the FDA has been successful for the two products;.
• An FDA
application under the 90-day “premarket notification” provisions of section
510(k) is expected to be submitted in the coming weeks.
• Renowned
wound care expert Dr. Brock Liden presented Clyra’s wound care technology at an
international wound care conference in Puerto Rico, highlighting its potential
to have a significant impact in wound care as well as potential in other areas
of medicine.
o Dr. Liden
confirmed to conference attendees that independent laboratory testing proves Clyra’s
products eliminate the “ESKAPE” pathogens while remaining gentle on skin tissue
Preview of AOS Symposium:
• The
BioLargo science team has been testing the AOS on three different real-world
wastewaters: dairy wastewater, poultry process water, and municipal secondary
effluent.
• Sharing
of impressive test results on real world problems by both the executive and
science teams.
• Discussion
of ongoing and future development of the commercial AOS and scale-up
considerations to accommodate high volume industrial uses.
• Various
options for AOS treatment train design depending on end-user needs.
Calvert acknowledged the role that public funding played in
the technology’s development history, “We have received over 35 grants related
to the advancement of this technology. We built a research center at the
University of Alberta and currently have more than 20 researchers advancing the
AOS.” He continued, “When we present our technology, we are armed with data and
credibility supporting a breakthrough technology that has a chance to make an
impact all over the world.”
Legal Disclaimer:
Except for the historical information presented herein,
matters discussed in this release contain forward-looking statements that are
subject to certain risks and uncertainties that could cause actual results to
differ materially from any future results, performance or achievements expressed
or implied by such statements. Flathead Business Solutions LLC, which owns
tamarackadvisorsinc.com, is not registered with any financial or securities
regulatory authority and does not provide nor claims to provide investment
advice or recommendations to readers of this release. Flathead Business
Solutions LLC may from time to time have a position in the securities mentioned
herein and may increase or decrease such positions without notice. For making
specific investment decisions, readers should seek their own advice. Flathead
Business Solutions LLC may be compensated for its services in the form of
cash-based compensation or equity securities in the companies it writes about,
or a combination of the two. For full disclosure please visit http://tamarackadvisorsinc.com/legal-disclaimer/.
No comments:
Post a Comment